Reduction of fibronectin expression by intravitreal administration of antisense oligonucleotides

Sayon Roy, Kathy Zhang, Timothy Roth, Serguei V Vinogradov, Richard S. Kao, Alexander Kabanov

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

We have investigated whether antisense oligonucleotides delivered intravitreally could reduce gene expression specifically in the retina. In this study, phosphorothioate antisense oligonucleotides targeted to fibronectin transcripts were coupled to a novel carrier and used to specifically reduce fibronectin (FN) expression in retinal vascular cells. Using confocal microscopy, fluorescence from fluorescein isothiocyanate- labeled FN-oligonuoleotides was detected in retinal vascular cells at 24 h postinjection and persisted until day 6 (the end point of this study). The fibronectin mRNA level was consistently decreased to 86.7% ± 7.9% of control (p<0.05) at day 2, and 46.7% ±4.9% of control (p<0.01) at day 6. In contrast, the β-actin mRNA level, an internal control, was unaltered in rat retinas that received FN-oligonucleotides. Fibronectin protein level at day 6 was also significantly reduced to 61.4% ± 16% of control (p<0.01). No toxic effect resulting from the carrier was detected histologically. Thus, intravitreal delivery of antisense oligonucleotides to modulate abnormal gene expression in retinal diseases may be an effective approach for ocular gene therapy.

Original languageEnglish (US)
Pages (from-to)476-479
Number of pages4
JournalNature Biotechnology
Volume17
Issue number5
DOIs
StatePublished - May 1 1999

Fingerprint

Antisense Oligonucleotides
Oligonucleotides
Fibronectins
Gene expression
Retinal Vessels
Gene therapy
Retina
Confocal microscopy
Phosphorothioate Oligonucleotides
Gene Expression
Rats
Retinal Diseases
Messenger RNA
Poisons
Fluorescence
Fluorescein
Proteins
Confocal Microscopy
Genetic Therapy
Actins

Keywords

  • Antisense oligonucleotides
  • Basement membrane
  • Block copolymer
  • Gene therapy

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Applied Microbiology and Biotechnology
  • Molecular Medicine
  • Biomedical Engineering

Cite this

Roy, S., Zhang, K., Roth, T., Vinogradov, S. V., Kao, R. S., & Kabanov, A. (1999). Reduction of fibronectin expression by intravitreal administration of antisense oligonucleotides. Nature Biotechnology, 17(5), 476-479. https://doi.org/10.1038/8654

Reduction of fibronectin expression by intravitreal administration of antisense oligonucleotides. / Roy, Sayon; Zhang, Kathy; Roth, Timothy; Vinogradov, Serguei V; Kao, Richard S.; Kabanov, Alexander.

In: Nature Biotechnology, Vol. 17, No. 5, 01.05.1999, p. 476-479.

Research output: Contribution to journalArticle

Roy, S, Zhang, K, Roth, T, Vinogradov, SV, Kao, RS & Kabanov, A 1999, 'Reduction of fibronectin expression by intravitreal administration of antisense oligonucleotides', Nature Biotechnology, vol. 17, no. 5, pp. 476-479. https://doi.org/10.1038/8654
Roy, Sayon ; Zhang, Kathy ; Roth, Timothy ; Vinogradov, Serguei V ; Kao, Richard S. ; Kabanov, Alexander. / Reduction of fibronectin expression by intravitreal administration of antisense oligonucleotides. In: Nature Biotechnology. 1999 ; Vol. 17, No. 5. pp. 476-479.
@article{23be7bb6f56449c39e1ef1097ee90c78,
title = "Reduction of fibronectin expression by intravitreal administration of antisense oligonucleotides",
abstract = "We have investigated whether antisense oligonucleotides delivered intravitreally could reduce gene expression specifically in the retina. In this study, phosphorothioate antisense oligonucleotides targeted to fibronectin transcripts were coupled to a novel carrier and used to specifically reduce fibronectin (FN) expression in retinal vascular cells. Using confocal microscopy, fluorescence from fluorescein isothiocyanate- labeled FN-oligonuoleotides was detected in retinal vascular cells at 24 h postinjection and persisted until day 6 (the end point of this study). The fibronectin mRNA level was consistently decreased to 86.7{\%} ± 7.9{\%} of control (p<0.05) at day 2, and 46.7{\%} ±4.9{\%} of control (p<0.01) at day 6. In contrast, the β-actin mRNA level, an internal control, was unaltered in rat retinas that received FN-oligonucleotides. Fibronectin protein level at day 6 was also significantly reduced to 61.4{\%} ± 16{\%} of control (p<0.01). No toxic effect resulting from the carrier was detected histologically. Thus, intravitreal delivery of antisense oligonucleotides to modulate abnormal gene expression in retinal diseases may be an effective approach for ocular gene therapy.",
keywords = "Antisense oligonucleotides, Basement membrane, Block copolymer, Gene therapy",
author = "Sayon Roy and Kathy Zhang and Timothy Roth and Vinogradov, {Serguei V} and Kao, {Richard S.} and Alexander Kabanov",
year = "1999",
month = "5",
day = "1",
doi = "10.1038/8654",
language = "English (US)",
volume = "17",
pages = "476--479",
journal = "Biotechnology",
issn = "1087-0156",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Reduction of fibronectin expression by intravitreal administration of antisense oligonucleotides

AU - Roy, Sayon

AU - Zhang, Kathy

AU - Roth, Timothy

AU - Vinogradov, Serguei V

AU - Kao, Richard S.

AU - Kabanov, Alexander

PY - 1999/5/1

Y1 - 1999/5/1

N2 - We have investigated whether antisense oligonucleotides delivered intravitreally could reduce gene expression specifically in the retina. In this study, phosphorothioate antisense oligonucleotides targeted to fibronectin transcripts were coupled to a novel carrier and used to specifically reduce fibronectin (FN) expression in retinal vascular cells. Using confocal microscopy, fluorescence from fluorescein isothiocyanate- labeled FN-oligonuoleotides was detected in retinal vascular cells at 24 h postinjection and persisted until day 6 (the end point of this study). The fibronectin mRNA level was consistently decreased to 86.7% ± 7.9% of control (p<0.05) at day 2, and 46.7% ±4.9% of control (p<0.01) at day 6. In contrast, the β-actin mRNA level, an internal control, was unaltered in rat retinas that received FN-oligonucleotides. Fibronectin protein level at day 6 was also significantly reduced to 61.4% ± 16% of control (p<0.01). No toxic effect resulting from the carrier was detected histologically. Thus, intravitreal delivery of antisense oligonucleotides to modulate abnormal gene expression in retinal diseases may be an effective approach for ocular gene therapy.

AB - We have investigated whether antisense oligonucleotides delivered intravitreally could reduce gene expression specifically in the retina. In this study, phosphorothioate antisense oligonucleotides targeted to fibronectin transcripts were coupled to a novel carrier and used to specifically reduce fibronectin (FN) expression in retinal vascular cells. Using confocal microscopy, fluorescence from fluorescein isothiocyanate- labeled FN-oligonuoleotides was detected in retinal vascular cells at 24 h postinjection and persisted until day 6 (the end point of this study). The fibronectin mRNA level was consistently decreased to 86.7% ± 7.9% of control (p<0.05) at day 2, and 46.7% ±4.9% of control (p<0.01) at day 6. In contrast, the β-actin mRNA level, an internal control, was unaltered in rat retinas that received FN-oligonucleotides. Fibronectin protein level at day 6 was also significantly reduced to 61.4% ± 16% of control (p<0.01). No toxic effect resulting from the carrier was detected histologically. Thus, intravitreal delivery of antisense oligonucleotides to modulate abnormal gene expression in retinal diseases may be an effective approach for ocular gene therapy.

KW - Antisense oligonucleotides

KW - Basement membrane

KW - Block copolymer

KW - Gene therapy

UR - http://www.scopus.com/inward/record.url?scp=0032937539&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032937539&partnerID=8YFLogxK

U2 - 10.1038/8654

DO - 10.1038/8654

M3 - Article

VL - 17

SP - 476

EP - 479

JO - Biotechnology

JF - Biotechnology

SN - 1087-0156

IS - 5

ER -